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ABSTRACT The severity of the toxic side effects of chemotherapy varies among patients, and much of this
variation is likely genetically based. Here, we use the model system Drosophila melanogaster to genetically
dissect the toxicity of methotrexate (MTX), a drug used primarily to treat childhood acute lymphoblastic
leukemia and rheumatoid arthritis. We use the Drosophila Synthetic Population Resource, a panel of
recombinant inbred lines derived from a multiparent advanced intercross, and quantify MTX toxicity as
a reduction in female fecundity. We identify three quantitative trait loci (QTL) affecting MTX toxicity; two
colocalize with the fly orthologs of human genes believed to mediate MTX toxicity and one is a novel MTX
toxicity gene with a human ortholog. A fourth suggestive QTL spans a centromere. Local single-marker
association scans of candidate gene exons fail to implicate amino acid variants as the causative single-
nucleotide polymorphisms, and we therefore hypothesize the causative variation is regulatory. In addition,
the effects at our mapped QTL do not conform to a simple biallelic pattern, suggesting multiple causative
factors underlie the QTL mapping results. Consistent with this observation, no single single-nucleotide
polymorphism located in or near a candidate gene can explain the QTL mapping signal. Overall, our results
validate D. melanogaster as a model for uncovering the genetic basis of chemotoxicity and suggest the
genetic basis of MTX toxicity is due to a handful of genes each harboring multiple segregating regulatory
factors.
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Methotrexate (MTX) is among the many chemotherapeutic medica-
tions prescribed to patients that have been shown to be very toxic
(Wecker et al. 2010). MTX is an antifoltate drug used primarily to
treat childhood acute lymphoblastic leukemia and rheumatoid arthri-
tis. Its toxicity includes gastrointestinal symptoms such as nausea,
vomiting, abdominal pain, and diarrhea; central nervous system tox-
icity; hepatitis with increased transaminase levels; serious or life-
threatening skin reactions; and decrease in the activity of the patient’s
immune system (http://www.nlm.nih.gov/medlineplus). Although MTX
is effective in the treatment of some patients, for others, its toxicity is
unbearable, and patients often are forced to change the dose or switch
to a different drug (Hardman et al. 1996; Rothenberg et al. 2001); in
the meantime, the disease progresses. This difference in a patient’s
ability to tolerate such toxic medications has often been attributed to
environmental factors such as diet, medical history, and age. However,
these factors do not explain all of the underlying toxicity (Gajewski
et al. 1989; Meirow and Nugent 2001; Rothenberg et al. 2001; Watters
and McLeod 2003; Lee et al. 2005), and there is strong evidence that,
alternatively, genes in concert with the environment govern toxicity
(Cirulli and Goldstein 2010). Although it is desirable to study the
underlying genetic architecture of MTX’s toxicity, doing so in humans
is difficult. Chemotherapy dosing often is personalized, a patient can
be taking several medications, and interindividual variation in envi-
ronmental factors such as age, weight, and diet makes genetic char-
acterization of toxicity challenging.
We have previously shown that there is a strong genetic component
to MTX toxicity, as quantified by the reduction in fecundity after a 3-d
MTX treatment regime, in female Drosophila melanogaster (Kislukhin
et al., 2012). In female D. melanogaster treated orally with MTX, the
observed reduction in fecundity is proportional to drug concentration
and treatment length and is therefore an objective and quantitative
way to measure chemotoxicity. It is not surprising that MTX affects
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the reproductive ability of D. melanogaster because MTX compet-
itively inhibits difolate reductase (DHFR). DHFR is needed for
DNA synthesis during cell replication; therefore, MTX inhibits cell
division required for reproduction of both humans and flies. With
D. melanogaster, it is also possible to standardize the environment
and hence maximize the power of an experiment to identify genetic
factors underlying the toxicity phenotype. We have previously
shown the reduction in fecundity after MTX exposure has a high
heritability (99%; Kislukhin et al. 2012), suggesting it is possible to
identify specific genes underlying the MTX toxicity in D. melanogaster
and their human orthologs.
A powerful approach to identifying the genetic factors underlying
complex traits is to use a collection of recombinant inbred lines (RILs)
derived from a synthetic population or “collaborative cross” type base
population (Churchill et al. 2004; MacDonald and Long 2007). Syn-
thetic populations cross multiple inbred founder lines for multiple
generations to create a population whose genomes are mosaics of
the original founder lines’ genomes. Panels using a synthetic pop-
ulation approach are expected to perform particularly well when
rare alleles of large effect underlie the trait of interest, for which
there are an increasing number of examples (e.g., Cohen et al. 2004;
Ji et al. 2008; Stefansson et al. 2008; Helbig et al. 2009; Nejentsev
et al. 2009; Pinto et al. 2010; Rivas et al. 2011; reviewed in Bansal
et al. 2010). Recently, the Drosophila Synthetic Population Re-
source (DSPR) was created as a community resource for the genetic
dissection of complex traits (http://FlyRILs.com; King et al. 2012a,b).
This panel consists of more than 1700 RILs generated from two
different 8-way, 50-generation synthetic populations. These RILs
are a stable genetic reference panel that allows for high-powered
and high-resolution quantitative trait loci (QTL) mapping in the
D. melanogaster model system.
Here, we use the DSPR to genetically dissect MTX toxicity as
measured by a reduction in fecundity in MTX exposed female flies.
We successfully map three QTL influencing MTX toxicity. Two of the
QTL are located in regions of the Drosophila genome harboring the fly
orthologs of human genes believed to mediate MTX toxicity (either
through their being in the biochemical pathway involved in processing
MTX or their harboring SNP that have been shown to have clinical
effects on toxicity). The third QTL was used to identify a novel can-
didate gene. We find little evidence that the underlying DNA poly-
morphisms explaining the QTL encode amino acid variants, instead
we speculate the genetic variation to toxicity is regulatory in nature.
This observation is apropos in light of the fact that human chemo-
toxicity pharmacogenomics has focused almost exclusively on amino
acid encoding variants. Local association scans of candidate gene
regions (using in silico derived genomes for the RILs) for toxicity
suggest that QTL cannot be explained by a single genetic polymor-
phism. We argue that variation for toxicity may be due to a handful
of genes each harboring several causative alleles.
MATERIALS AND METHODS
Preliminary drug delivery and dose2response assay
We performed dosing experiments to determine the dose response
effect of MTX. Eight doses (varying 36-fold plus a placebo, no drug,
control) of MTX were mixed with liquid food, spread onto a 1-cm ·
2-cm piece of Whatman filter paper (cat. no. 3030 392), and placed
into an agar plug at the bottom of a plastic exposure vial. Twelve 3-d-
old male and female flies were placed in each of six exposure vials per
dose, exposed to drug/food or placebo/food filter papers for 3 d, and
then transferred to recovery vials for one day. After recovery, four
females were chosen at random from each recovery vial and placed
individually in separate “lay-out” vials, allowed to lay eggs for 3 d, and
discarded (see Supporting Information, Table S1 for recovery and lay-
out food composition). Two weeks after the mothers were discarded
from the lay-out vials, the offspring were recovered and counted.
We chose the final dose for the MTX toxicity phenotype experiment,
based on a 50% fecundity decrease, as 110 mM.
Mapping population
We used RILs from the DSPR (http://FlyRILs.com) to map QTL for
MTX toxicity. The DSPR is a multifounder advanced intercross panel
consisting of a set of more than 1700 RILs of Drosophila melanogaster.
Two 8-way synthetic populations (pA and pB) were created from two
independent sets of seven inbred founder lines (A12A7 or B12B7)
with one additional line (AB8) shared by both populations. Each
synthetic population was maintained as two independent replicate
subpopulations (pA1 and pA2 or pB1 and pB2), kept at a large
population size, and allowed to freely recombine for 50 genera-
tions. At generation 50, each subpopulation gave rise to ~500 RILs
via 25 generations of full-sib mating. The genomes of the original
15 inbred founder lines have been completely resequenced, and the
complete underlying founder haplotype structure of all RILs in the
panel has been determined via a hidden Markov model (HMM).
Complete details of the development of the DSPR, founder whole
genome resequencing, and RIL genotyping are described in King
et al. (2012a). The development of the HMM to infer the mosaic
structure of the RILs and the power and mapping resolution of the
DSPR for QTL mapping are described in King et al. (2012b). All of
the raw genomic data and inferred founder genotype data are freely
available at http://FlyRILs.org.
The MTX toxicity phenotype
Rather than directly phenotype the RILs for toxicity, to avoid
potentially mapping QTL for inbreeding depression, we chose to
phenotype F1 individuals from matched crosses between pA1
males and pB2 females or pA2 males and pB1 females (Figure 1A).
We arbitrarily crossed A/B RILs with the same line number (i.e.,
pA11pB21, . . . , pA1npB2n, pA21pB11, . . . , pA2mpB1m). We
performed 396 pA1 male to pB2 female and 302 pA2 male to
pB1 female crosses during the course of 8 weeks. For each cross,
five virgin females from the pB population were mated to five males
from the pA population in each of two vials with parents cleared
after 4 d. The vials were left at 23 for 8 more days, and 12 F1 brother-
sister mated adult males and females were collected for exposure to
MTX. Generally all 24 flies exposed to MTX came from the same vial
(~80% of the time), although occasionally we needed additional off-
spring from the backup vial. Each week we attempted ~120 crosses,
although not all crosses produced enough offspring to proceed to the
next step, leading to ~100 successful crosses per week.
Three females and three males were each placed in three “treat-
ment cells” in a device we call a fly condo, and a fourth “control cell”
was placed in a second condo. Fly condos consist of an array of “cells”
with dimensions similar to a standard vial, except the top is a fine
mesh screen, and the bottom (containing food) can be removed from
the entire condo at one time. Experimentally the condos allow us to
anesthetize an entire array of flies simultaneously and quickly change
from standard food to MTX food. In the MTX experiment described
here any given treatment condo contained four different crosses
(= genotypes) each exposed in triplicate to MTX with each exposure
cell having three males and three females exposed. Flies were placed in
the condos and immediately exposed to MTX for 3 d. MTX (catalog
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no. M1676; LKT Laboratories, Inc,) was diluted in DMSO to 2.2 mM,
then mixed with liquid food (12.5 g of sucrose, 17.5 g of active dry
yeast, 5 mL of Karo light corn syrup, 95 mL phosphate-buffered saline;
autoclaved before use) to a final concentration of 110 mΜ, and 100 mL
was then spread onto a 1-cm · 2-cm piece of Whatman filter paper
(cat. no. 3030 392) and placed into a 1-inch high agar plug at the
bottom of each fly condo cell. We have previously shown this to be an
effective drug delivery method (Kislukhin et al. 2012).
After the 3-d exposure, flies were anesthetized with CO2, the bot-
tom of the condo containing the MTX was replaced with standard
food, and flies were allowed to recover for 24 hr. After the 24-hr
recovery, we provided the flies with new standard food, allowed them
to lay eggs for 48 hr, and then discarded the adults. The progeny
produced by the treated F1 females were given an additional 14 d
to develop into adults, at which point we froze the condos, then re-
moved the offspring by transferring them to a “sandwich” of two GBC
SelfSeal Repositionable Letter Size Laminating Sheets, 3 mil. To ensure
accuracy, we triple counted the offspring from each cell and used the
mean over the three cells as our estimate of fecundity. Thus mated
female fecundity after a 3-d exposure to MTX is our measure of
toxicity of MTX. All of the phenotype data described here is available
at http://FlyRILs.org and has been deposited in the Dryad Repository:
http://dx.doi.org/10.5061/dryad.d20qc.
Control flies were handled the same as experimental flies except
they were only exposed to a mock treatment consisting of dimethyl
sulfoxide and liquid food. After the 3-d exposure, as opposed to a
24- hr recovery followed by 2 d to lay eggs, the mock treatment flies
were given only 24 hr to lay eggs with no recovery. After 14 more
days, we froze the condos containing the progeny of treated flies and
visually inspected each chamber for the presence of flies. In most cases
the cells were “saturated” (see Figure S1A). That is, they appeared
to contain close to the maximum number of progeny a cell could support
(generally .100 offspring), so they were not individually counted. We
primarily used the control group to identify crosses that resulted in
poor female fecundity—we removed crosses resulting in fewer than
50 offspring from further analysis.
We estimated the saturation point of the condo wells to determine
the top-end of the “dynamic range” of our assay. To determine condo
saturation, a total of 48 wells were filled with five pairs of flies each,
and the flies were allowed to lay eggs for 2 d. After 2 wk, the number
of offspring was counted to determine condo saturation (Figure S1A,
light grey bars). We compare these saturated cells to the number of
offspring we see in each cell in our experiment for the four blocks we
analyzed. Two things are apparent from Figure S1A: (1) in the no drug
saturation2treated cells (where females are likely to have laid..100
viable eggs) we are seeing the vials beginning to saturate at between
100 and 125 offspring (that is ~10% of our saturated cells have be-
tween 100-125 offspring), and (2) despite the wells having a saturation
point, the vast majority of MTX-treated cells show many fewer off-
spring. In our actual experiment we only have three females to at-
tempt to have the majority of the vials well below saturation levels.
Overall fecundity knockdown at our optimal oral methotrexate
dose (of 110 mΜ) was determined on the basis of the number of
offspring laid by three pairs of F1 hybrid brother-sister2mated
D. melanogaster from pA1xpB2 crosses carried out in half-pint round
bottom glass stock bottles. We treated 16 genotypes (pA245pB145,
pA247pB147, pA252pB152, pA253pB153, pA259pB159, pA260pB160,
pA261pB161, pA268pB168, pA270pB170, pA271pB171, pA274pB174,
pA278pB178, pA280pB180, pA281pB181, pA282pB182, and pA283pB183)
using our standard dosing protocol in condos. Three treated sets of
Figure 1 Experiment Design.
(A) Each pair of RILs was
crossed to produce the F1 hy-
brid. The hybrids were raised
to adulthood, brother-sister
mated, and placed into condo
wells (three males and three
females per well). Each condo
contained four RIL crosses ex-
posed to MTX simultaneously.
After a 3-d exposure, each
condo was recovered for 1 d,
and the flies were allowed to lay
eggs for 2 d after the recovery
stage, after which the adult flies
were cleared out of the condo.
The eggs developed into adults
for 14 d after the condos
were cleared, frozen at 220,
and transferred onto adhe-
sive sheets for counting. (B)
The entire assay was split into
eight blocks, with start dates
on consecutive weeks. Each
block took 8 wk to complete.
F1 hybrids from populations
A1·B2 were assayed over the
first 3 wk, and any crosses that
failed to complete the entire cy-
cle were repeated in weeks 6 and 7. F1 hybrids from populations A2·B1 were assayed in weeks 4 and 5, and the crosses that failed in those two
weeks were completed in week 8. (C) Density plot of the mean number of offspring produced by the three replicate females from each RIL.
Different colors correspond to different weeks (blocks) of the experiment.
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three male and three female flies per genotype were then allowed to
lay eggs for 48 hr in condos. One mock-treated set of three male and
three female flies per genotype was placed into a half-pint round-
bottom glass stock bottle. The reason for allowing the mock treated
flies to lay-out in bottles was to avoid saturation of the condos. After
2 wk, the offspring produced were counted to determine the control
fecundity level (Figure S1B). The results from the bottles were com-
pared with the numbers of offspring produced by the MTX treated
pairs of the same genotypes in condos. At the dose used we appear to
have a ~50% reduction in fecundity, with considerable bottle-to-bottle
or genotype-to-genotype variation about that reduction.
The entire assay from start (crossing pA and pB RIL parents) to
finish takes 6 wk; thus, the experiment was performed over eight
overlapping weeks (Figure 1B). In the first 3 wk we attempted 396
pA1pB2 crosses and in weeks four and five we attempted 302
pA2pB1 crosses. Weeks six through eight were used to repeat crosses
that failed the first time around.
A priori candidate genes
Despite the fact chemotoxicity assays are difficult to perform in
humans, it is possible to identify a priori human candidate genes for
methotrexate toxicity based on the methotrexate cellular pathway
(Figure 2, Table S2). We identified additional candidate genes from
publications by using a PubMed search with key words “methotrex-
ate”, “toxicity,” and “polymorphism.” The resulting set of 137 publi-
cations was then manually curated to identify only those publications
in which the patient’s germ line genotype (not a tumor’s genotype) at
a gene impacted toxicity (Table S2). We limited our search to studies
in humans and did not include any studies in which the polymor-
phisms’ effects on toxicity were not statistically significant (there is
considerable heterogeneity in the literature as to what warrants statis-
tical significance). After identifying the a priori candidates, we used
the ensembl.org browser to identify the orthologs of those genes in
D. melanogaster; the ortholog types are listed along with D. melanogaster
gene names in Table S2. The remaining human candidate genes listed
in Table S2 are not associated with publications reporting a germline
genetic polymorphism impacting MTX toxicity, although they are
believed to be in the pathway that processes MTX, based on bio-
chemical studies. The role of these “pathway implicated” genes is
discussed most fully in a recent review by Mikkelsen et al. (2011).
Glutathione S-transferase (GST) is a strong human a priori candidate
gene family with known pharmogenetic polymorphisms, but Ensembl’s
fly ortholog prediction seems incorrect, we define the human GST fly
orthologs to be the two Drosophila regions harboring tandemly re-
peated GST gene families.
Data analysis
All data analysis was performed in R (R Development Core Team
2012). We used a mixed-model analysis of variance by using the lme
function in the nlme package (Pinheiro et al. 2012) to test for an effect
of week (block) on MTX toxicity. Cross ID and week were random
effects with cross ID nested within week. A likelihood ratio test
showed a highly significant effect of week (x1 = 397.9 p , 0.0001).
Visually, weeks 6, 7, and 8 all had much lower knockdown of off-
spring, and the number of offspring produced was near condo satu-
ration level (Figure 1C). Week 4 showed the opposite pattern, where
the knockdown was too high with many of the females producing zero
offspring (Figure 1C). Because we felt these weeks did not represent
our target phenotype, in all subsequent analyses, we ignored these four
weeks, and only used the weeks with mean fecundity knockdown near
50%, roughly the same trait studied in our earlier work (Kislukhin
et al. 2012). Dropping weeks 4, 6, 7, and 8 reduced our total number
of crosses/genotypes to 307 for all further analyses.
Heritability and MTX QTLs
We estimated the broad sense heritability of MTX toxicity by estimating
the genetic and phenotypic variance components from a linear mixed
model using the lme and VarCorr functions in the nlme package
(Pinheiro et al. 2012). Note that because all three replicates were
reared in the same condo (although different cells), these heritability
estimates include some microenvironmental effects. We estimated the
heritability of cross means as the estimated genetic variance compo-
nent over the total variance of cross means. Heritability estimates were
obtained from the censored collection of 307 pA male to pB female
crosses.
The general analytical framework for QTL mapping in the DSPR is
described in King et al. (2012a,b). One of the features of the DSPR is
that the underlying mosaic haplotype structure of every RIL is known
with a high degree of certainty via an HMM (King et al. 2012b). For
each position in each RIL in the DSPR panel, the HMM has assigned
the probability that the founder genotype is 1 of the 36 possible
founder genotype combinations (8 homozygous possibilities, 24 het-
erozygous possibilities). These assignments are made at evenly spaced
positions across the genome, every 10 kb. The vast majority of the
genomes of the RILs are homozygous, and we therefore converted the
36 founder genotype probabilities to eight additive probabilities
by assuming any heterozygous states are intermediate to the two
Figure 2 MTX cellular pathway. MTX enters cancer cells via the
reduced folate carrier, and the efflux across the cell membrane is
mediated by various ABC transporters. Inside the cell, MTX is
converted to active methotrexate polyglutamates by folylpolygluta-
mate synthetase (FPGS), which adds glutamate residues to MTX. The
primary action of MTX is inhibition of the enzyme dihydrofolate
reductase (DHFR), which converts dihydrofolate to tetrahydrofolate.
The effect of MTX depends on the function and expression of several
other enzymes in the folate pathway, including methylenetetrahydro-
folate dehydrogenase, 5,10-methylenetetrahydrofolate reductase, and
thymidylate synthetase. Degradation of MTXPGs to MTX depends on
the activity of the lysosomal enzyme GGH, which catalyzes the removal
of polyglutamates (Mikkelsen et al. 2011). AMP deaminase (AMPD1)
converts adenosine monophosphate (AMP) to inosine monophos-
phate (IMP). Adenylosuccinate synthase (ADSS) and adenylosuccinate
lyase (ADSL) counteract the action of AMPD1, convert IMP back to
AMP in a two-step process. Adenylate kinase catalyzes the formation
of two molecules of ADP from AMP and ATP; ADP is the substrate for
oxidative phosphorylation that forms ATP. GSTs are not known to di-
rectly interact with methotrexate but are main mediators of detoxifi-
cation by conjugation of xenobiotics with glutathione.
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homozygous states. To perform QTL mapping, we regressed mean
MTX toxicity for each cross on the 16 additive probabilities corre-
sponding to the probabilities the paternal RIL was derived from each
of the pA founders and the probabilities the maternal RIL was derived
from each of the pB founders and included subpopulation as a cova-
riate. We did not include the random effect of condo in the QTL
analysis. Although any given condo held four specific crosses, founder
genotypes at each position occur in many different crosses and thus
across many different condos. In addition, given that there were only
four crosses per condo and each cross occupied a single condo, cross
ID and condo are confounded, and by including condo in the model
as a covariate we likely remove some of the genetic variance we are
attempting to explain. Thus, the model is as follows:
y ¼ mþ bsSþ
X7
i¼1
bA;iGA;i þ
X7
i¼1
bB;iGB;i;
where m is the grand mean; S is subpopulation; GA,i are the genotype
probabilities for the paternal RIL; GB,i are the genotype probabilities
for the maternal RIL; and bs, bA,i, and bB,i are the corresponding
effect estimates. Because we assayed females, the model for the X
chromosome is the same as for the autosomes. Some founder geno-
types were poorly represented in the crosses we assayed at some
locations in the genome (i.e., fewer than five crosses have that
founder genotype at that genomic position). We found that includ-
ing these terms, with little representation, in the model could lead to
inflated p-values. Therefore, at a given position, if the sum of the
probabilities across all the crosses assayed for a given founder geno-
type probability was less than 4.8, we dropped that term from the
model (the result is that the model degrees of freedom vary with
genomic position). Including week as a block effect gave very similar
results (data not shown) and thus, for simplicity, we present the
results from the model without the effect of week here. At each
position, we calculated the F-statistic for the overall effect of geno-
type and obtained –log10(p-values). We then used the loess smooth-
ing function in R with a span of 0.005 to smooth the –log10(p-values)
across genetic distance to temper any highly localized fluctuations
(cf. Paterson et al., 1988).
We estimated the effects of each founder genotype at each QTL
separately for each population (pA and pB). To do this, we fit the
following model: yr ¼
P8
i¼1 biGi, where yr are the residuals after
correcting for subpopulation, Gi are the founder genotype probabili-
ties, and bi are the corresponding effect estimates. Once again, only
founder genotypes whose sum across all crosses was greater than 4.8
were included.
We performed 1000 permutations of the data to determine genome-
wide significance thresholds (Churchill and Doerge 1994) for several
false-positive rates. For each permutation, we smoothed the result-
ing –log10(p-values) as we did for the observed data with the same
loess smoothing function. We then used the peak finder function
msPeakSimple from the msProcess library (Gong et al. 2012) in R with
a span of 50 and a signal to noise threshold of 1 to identify distinct
peaks across the genome. For a wide range of potential –log10(p-value)
thresholds, we quantified the number of distinct peaks per genome
scan for each permutation that exceeded that threshold. We could then
calculate the number of observed peaks exceeding a given –log10(p-value)
threshold per genome scan and determine a range of false positive rates.
For example, the –log10(p-value) threshold that corresponds to 0.05
peaks per genome scan is our threshold corresponding to a 5% false
positive rate. We show false-positive rates ranging from 0.05 to 3
expected peaks per genome scan.
We identified and localized peaks of interest using the smoothed
–log10(p-values) as described previously. We considered a peak to be
a peak of interest if one of the following conditions was met: (1) the
peak colocalized with a D. melanogaster ortholog of a known MTX
toxicity candidate gene identified a priori and had a p-value , 0.01
(see Materials and Methods), or (2) the –log10(p-value) exceeded our
0.5 genome-wide false-positive rate threshold (i.e., a 50% chance of
a single false-positive genome wide). To obtain confidence intervals on
these peaks, we performed a genome scan without dropping founder
genotype terms with poor representation and we converted the result-
ing F-statistic to a logarithm of odds (LOD) score (Broman and Sen
2009). We did not drop founder genotype terms when determining
confidence intervals to keep the degrees of freedom for the model
constant as variations in the degrees of freedom alter the relationship
between LOD scores and p-values and alter the amount of LOD drop
corresponding to a given percent confidence interval (Manichaikul
et al. 2006; Broman and Sen 2009; King et al. 2012b). We used these
LOD scores to calculate confidence intervals in two ways. First, we
used a traditional 2 LOD drop interval. However, whereas 2 LOD intervals
are conservative for two line crosses, the necessary LOD drop increases for
larger degrees of freedom in the model (Manichaikul et al. 2006) and we
have previously shown they are overly liberal for our 8-way crosses (King
et al. 2012b). We also calculated Bayes credible intervals, for which 95%
coverage is more consistent for different sample sizes, experimental
designs, and effect sizes (Manichaikul et al. 2006; Broman and Sen 2009).
We explored multiple QTL models for subregions in which we
appeared to identify two closely linked QTL. We performed both local
2D genome scans surrounding these regions and performed genome
scans after statistically correcting for each of these QTL. In both cases
we dropped founder genotype probabilities that did not sum to at least
4.8 as indicated previously. The local 2D scans were performed by
fitting the following model:
y ¼ mþ bsSþ
X7
i¼1
bA;i;1GA;i;1 þ
X7
i¼1
bB;i;1GB;i;1
þ
X7
i¼1
bA;i;2GA;i;2 þ
X7
i¼1
bB;i;2GB;i;2
where m is the grand mean; S is subpopulation; Gi are the genotype
probabilities for population A and B at position 1 and 2; and bs,
bA,i,1, bB,i,1, bA,i,2, and bB,i,2 are the corresponding effect estimates.
We considered a 14-cM region surrounding our QTL of interest and
fit all possible pairs of positions in this region. Linkage limits our
ability to distinguish very closely linked QTL and we only tested
pairs of positions at least 2 cM apart. We also performed two ge-
nome scans after statistically correcting for two of our most signif-
icant QTL. We fit the following model:
yr ¼ mþ
X7
i¼1
bA;iGA;i þ
X7
i¼1
bB;iGB;i;
where yr are the residuals from the best fitting single QTL model;
m is the grand mean; Gi are the founder genotype probabilities for
population A and B; and bs, bA,i, and bB,i are the corresponding
effect estimates.
Testing the effects of SNPs and transposable element
(TE) inserts in candidate genes and candidate
gene regions
The four QTL peaks identified were associated with seven candidate
genes: A with CG32626, B with GstE1–Gst E10 (a tandemly repeated
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gene complex), C with PHGPx, and D with CG32154 and CG32155,
Gnf1, Prat, and pug (the justification for these candidate genes is
discussed more fully in the Results and Discussion). For each candi-
date gene we somewhat arbitrarily defined an upstream and down-
stream limit to that gene to be the region bounded by the next gene’s
up- or down-stream coding region rounded to the nearest kilobase.
These candidate gene regions are given in Table S3. Within each
candidate gene region we identified three types of biallelic genetic
polymorphisms: nonsynonymous SNPs (i.e., SNPs predicted to en-
code an amino acid variant), other SNPs (including both synonymous
SNPs, SNP in UTRs, and SNPs outside the coding regions), and
segregating TE insertions. To determine whether amino acid2encoding
SNPs explain linkage peaks, for QTL with one or more clear can-
didate genes, we identified all possible SNPs in the founder lines
that are predicted to encode amino acid variants. For details on
how we called SNPs in the founder lines, see King et al. (2012a;
http://FlyRILs.org). We then inferred the probability each RIL har-
bored the minor allele and assigned a genotype value to each cross
by adding the paternal and maternal probabilities. In the case of
perfect certainty, genotype values are: 2 = AA, 1 = Aa, and 0 = aa.
We then fit the following single marker model for each possible
amino acid variant:
y ¼ mþ bsSþ bmM;
where S is subpopulation,M is the cross genotype at the marker, and
bs and bm are the corresponding effect estimates. We also fit this
model for 50 randomly selected SNPs that fell within the widest
confidence interval for each identified QTL to obtain a null expec-
tation for SNPs linked with our QTL. We carried out a similar
analysis for the nonsynonymous SNPs in the candidate gene inter-
vals. We additionally had access to a set of unpublished annotations
of TE insertions segregating in the founders (J. M. Cridland, S. J.
MacDonald, A. D. Long, and K. R. Thornton, unpublished results),
of which there were four segregating in candidate gene intervals (at
X:13727665, 2R:14293010, 2R:14294252, and 3L:16227431 in A, B,
B, and D, respectively), we also tested each of these TE insertions for
an association with MTX toxicity. Aside from correcting for sub-
population, we did not correct for kinship among the lines. Within
subpopulations, kinship is fairly even among the lines and we do not
expect it to have a large effect.
RESULTS
We used female fecundity as a measure of MTX chemotoxicity in 698
pA RIL male by pB female crosses over eight experimental blocks
(Figure 1B). The fecundity of a pool of three females in three replicate
vials was assayed for each genotype (Figure 1A). Female fecundity is
a reliable indicator of heritable toxicity (Kislukhin et al. 2012). For
reasons beyond our experimental control three of the weeks (blocks)
showed very little fecundity knockdown (with counts approaching vial
saturation levels), and a fourth week (block) showed extremely high
knockdown (Figure 1C). Although we cannot pinpoint the exact
cause of this shift in mean fecundity over time, we propose that the
drug2food solution was not homogeneous in those weeks, where
some condo wells had almost no drug, whereas the other wells had
much greater concentrations. We decided to remove these blocks
from further consideration to ensure we were mapping QTL associ-
ated with a knockdown of ~50%, this decision results in a dataset
consisting of 307 RIL cross pairs (Figure 3). Substantial variation
existed among crosses in MTX toxicity as measured by the number
of offspring produced after MTX exposure (Figure 3). We estimated
broad sense heritability of MTX toxicity to be 0.38. For QTL mapping,
we used the mean MTX toxicity (over the three replicate vials per
cross) and thus we also estimated the broad sense heritability of
genotype mean MTX toxicity, which is 0.64. Both of these estimates
are much lower than the narrow sense heritability we estimated in
a previous study using a similar assay (Kislukhin et al. 2012; see
Discussion).
Our genome scan identified three QTL regions of interest, labeled
A-C (Table 1; Figure 4A). Two of these QTL (A and C) exceed the 0.5
genome-wide false-positive threshold (given that the expectation at
this threshold is 0.5 false positives and we observe 2 QTL, this corre-
sponds to a false discovery rate of 25%) with QTL C, the most sig-
nificant peak, also exceeding the 0.2 threshold. QTL B did not exceed
the 0.5 threshold; however, it corresponds to known candidate gene
(see below), and had a marginal p-value of 0.007 so it of interest. An
additional QTL region, QTL region D, was not significant as deter-
mined by our criteria, and it spans the centromere of chromosome
3 (so resolution is poor); nonetheless we discuss it in this section as
the interval defined by this QTL includes several a priori candidate
genes and the architecture of the peak mirrors this cluster of can-
didate genes. These three QTL each explain between 15% and 20%
of the genetic variation in MTX toxicity (Table 1), and together
they explain ~45% of the total genetic variation. The total genetic
variation explained is very similar if we fit a model that fits all three
QTL simultaneously, or simply sum over the variance explained by
each QTL individually, not an unexpected result given the large
number of genotypes and unlinked QTL. We were able to resolve
QTL A, B, and C to ~3 – 4 cM (~7002900 kb, Table 1). QTL D is
a wide peak that spans the centromere of chromosome 3 and there-
fore resolution for this QTL was much lower at ~5–8 cM (~12–17
Mb; Table 1).
We estimated the phenotype effects of each founder haplotype on
MTX toxicity for the two QTL exceeding our 0.5 genome-wide false-
positive rate. The estimated effects of each founder genotype do not
show a pattern suggesting simple biallelism (Figure 4, B and C).
However, factors such as multiple linked QTL in the region, multiple
alleles for a single causative gene, non-additivity of founder genotypes,
or variation in the frequency of founder genotypes in the two pop-
ulations could make the effects at our QTL difficult to estimate or
interpret.
The A and C QTL regions both showed smaller nearby peaks
(Figure 4A). In both cases the satellite peak was close to the major
peak and separated by a trough in likelihood. To help determine
whether these loci represented multiple distinct QTL, we performed
local 2D genome scans and full genome scans after statistically con-
trolling for each of QTL A and C. Linkage limits our ability to dis-
tinguish very closely linked QTL and we only tested pairs of positions
at least 2 cM apart. The local 2D scans confirmed the single QTL
results, showing the most significant results only when the most sig-
nificant single QTL was included in the model. The most significant
p-value for both local 2D scans (QTL A: 2log10(P) = 4.39; QTL
C: 2log10(P) = 4.44) was not substantially more significant than our
most significant single QTL models (QTL A: -log10(P) = 3.19; QTL
C: 2log10(P) = 3.5). In addition, performing genome scans after sta-
tistically correcting for each of QTL A and C (Figure S2) did not show
any additional peaks in the region of the QTL corrected for, nor did we
observe any new QTL co-localizing with known candidate genes or
exceeding our 0.5 threshold. Given we do not have strong evidence that
QTL regions A and C represent multiple QTL, we treat them as single
regions, however, it is possible future studies with larger sample sizes
may reveal multiple QTL in these regions.
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Two of the three mapped, QTL are associated with fly
orthologs of human genes believed to be important in
MTX toxicity:
We identified a total of three significant (at our criteria outlined
previously) QTL, labeled A-C (Figure 4A; Table 1). Of these three,
two lie directly over the fly orthologs of human genes in the
methotrexate pathway (Table S2; Table S3; Figure S3). These three
QTL encompass 2.46MB in total (the sum of the Bayesian credible
intervals of Table 1). Including only regions of the genome with
typical levels of recombination (X: 2.5221 Mb, 2L: 1217.5 Mb,
2R: 7219 Mb, 3L: 1219 Mb, 3R: 7224 Mb), where it is possible to
genetically locate to submegabase scales, the fine-map-capable fly
genome is 82 Mb. Because we have 15 fly orthologs of human
candidate genes in the 82-Mb fine-map-capable fly genome (Table
S2), the probability of observing two or more candidate genes
under of mapped peaks is 7.5% (i.e., 1 2 ppois(1,15(2.46/82))).
Although this is not a formally significant enrichment for candi-
date genes, a p-value of 7.5% is suggestive of enrichment. In ad-
dition, the particular candidate genes are very strong because they
harbor pharmacologically relevant genetic polymorphisms that
impact MTX toxicity and are in the MTX toxicity pathway (Table
S2). If we ask whether there is an enrichment for the subset of six
candidate genes that have pharmacologically relevant polymor-
phisms and fly orthologs the p-value for enrichment is 1.4% (i.e.,
1 2 ppois(1,15(2.46/82))).
QTL A includes the candidate gene CG32626, an ortholog of the
human gene adenosine monophosphate deaminase 1 (AMPD1).
Patients with rheumatoid arthritis treated with methotrexate carrying
the C34T allele of the AMPD1 gene were shown to have better clinical
response to the drug (Wessels et al. 2006). QTL B lies over a gene
family, GSTE12GSTE10, consisting of orthologs of the glutathione S
transferase (GST) gene, previously associated with high hepatotoxicity
in lymphoblastic leukemia and malignant lymphoma methotrexate
treatment (Imanishi et al. 2007).
The rather broadly peaked QTL D is not significant based on
our criteria and spans a centromere but nonetheless includes several
candidate genes. The peak is much broader than those typically
observed so it is conceivable this peak is associated with multiple
linked genes. Genes CG32154 and CG32155 are orthologs of the hu-
man Gamma-glutamyl hydrolase (GGH) gene. This gene is involved in
the methotrexate pathway (Figure 2) and has been shown to be asso-
ciated with methotrexate efficacy and toxicity in Japanese patients
with articular-type juvenile idiopathic arthritis (Yanagimachi et al.
2011). Gene Gnf1 is a 1-to-1 ortholog of the human replication factor
C subunit 1 (RFC-1) gene, which encodes a major methotrexate trans-
porter. The mutation G80A in RFC-1 has been associated with post-
methotrexate treatment survival of children with acute lymphoblastic
leukemia. Children with the GG genotype had better prognoses than
those with the GA, and the AA genotype had the worst outcome
(Laverdiere et al. 2002). Prat is an ortholog of the human gene PPAT,
which is a member of the purine/pyrimidine phosphoribosyltransferase
family. PPAT along with GART and ATIC is involved in the de
novo purine synthesis of the methotrexate pathway (Figure 2). The
D. melanogaster gene pug is an ortholog of the human methylenete-
trahydrofolate dehydrogenase 1 (MTHFD1) gene, which is part of the
methotrexate pathway (Figure 2). Additionally, the C677T mutation in
this gene has been associated with hematologic and liver toxicity during
consolidation and maintenance treatment toxicity in acute lymphoblas-
tic leukemia in children (Costea et al. 2006).
QTL C identifies novel candidate genes for MTX toxicity
QTL C spans 122 fly genes, none are fly orthologs of our human
a priori candidate genes (Table S2). In the absence of a priori candi-
dates for this peak, genes worthy of additional consideration were
determined by manual curation of the region. We were able to identify
a single gene that appears to be closely related to methotrexate activity:
fly gene PHGPx, having human ortholog GPx4 (Imai and Nakagawa
2002). GPx4, which codes for the glutathione peroxidase protein, is
Figure 3 (A) Means and SEs of
the number of offspring pro-
duced by each F1 female from
each pA-pB cross. Different col-
ors correspond to different weeks
(blocks) of the experiment after
removing weeks with poor dos-
ing. (B) Density plot of the mean
number of offspring produced by
the three replicate females from
each RIL. Different colors corre-
spond to different weeks (blocks)
of the experiment.
n Table 1 Details of identified QTL
Name Peak Location, Mb -log10(p-Value) 2-LOD CI, Mba 2-LOD CI, cMa BCI, Mbb BCI, cMb Percent of H2c
A X 13.85 3.19 13.25–14.60 43.01–48.37 13.48–14.31 44.02–47.35 0.15
B 2R 14.00 2.13 13.82–14.38 84.06–85.72 13.84–14.31 84.12–85.52 0.12
C 3L 3.42 3.5 2.79–3.84 4.61–8.58 3.02–3.98 5.45–9.11 0.19
D 3L 22.24 1.92 3L:17.76–3R:5.85 44.76–49.25 3L:14.78–3R:7.5 42.08–49.25 0.10
QTL, quantitative trait loci.
a
2-LOD CI indicates 2 LOD support intervals.
b
BCI are Bayesian credible intervals.
c
Percent of H2 refers to the percent of broad sense heritability of cross means.
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a unique antioxidant enzyme shown to reduce phospholipid hydro-
peroxide in mammalian cells (Imai and Nakagawa 2002). This gene
has decreased expression levels in renal rat tissue (Oktem et al. 2006)
and in the spinal cords of rabbits (Ayromlou 2011) in the presence of
methotrexate.
QTL peaks are not due to amino acid polymorphisms in
candidate genes
Predicted amino acid encoding variants in our seven candidate genes/
gene regions (Table S3) explain only a modest amount of the herita-
bility of cross means (ranging from near 0% to 3.8%) and much less
than the QTL themselves, explaining at most 25% of the variance
explained by any given QTL. We also tested a random set of 50 SNPs
that fell within the widest confidence interval of each peak. In all cases,
at least one of the randomly selected SNPs explained a larger pro-
portion of the heritability than all of our identified potential amino
acid variants. We therefore conclude our QTL are unlikely to be
explained by coding variants in the candidate genes we identified.
Noncoding SNPs in candidate gene regions may
be causative
For all SNPs segregating among the founders we inferred genotypes in
the RILs and carried out a gene-centric association study. By focusing
on small genomic intervals containing only a handful of SNPs, we
found that the statistical threshold for significance is greatly reduced.
These gene-centric association scans are depicted in Figure S4, and the
subset of SNPs having suggestive significance are presented in Table
S4. One SNP in CG32626 gene region (QTL A; base 13739344)
reached Bonferroni significance and may explain as much as 10% of
the genetic variation in MTX toxicity. Upon closer inspection of the
raw Illumina read data this “SNP” is actually a small insertion deletion
polymorphism with 8 of the 15 founders having deletions of a “G”
rich tract ranging from 26 to 38 bases in size (Figure S5). This INDEL
is ~50 bp downstream of the donor site for the five prime most first
exon of CG32626. Because this gene is annotated using four different
first exons, we hypothesize that it may impact splicing in some man-
ner. A second SNP in the PHGPx gene region (3L:3339692) did not
reach Bonferroni significance but was highly suggestive. This SNP is
located downstream of this gene (which is located entirely in the
intron of another gene) in a region that modENCODE annotates as
an “active promotor/transcription start site” in both S2 and BG3 cells.
Insertions of TEs in candidate gene regions
We tested for associations between four TE located in the candidate
gene regions and MTX toxicity. Neither TE under QTL B was
significantly associated with MTX toxicity, although both the TE
under QTL A (X:13727665) and QTL D1 (3L:16227431) were
significantly associated at p,0.0004 and p,0.0027 respectively.
But these p-values must be interpreted with caution, in the DSPR it
is difficult to attach meaning to an event only present in a single
founder, since that event tags an entire local haplotype. That being
said, the TE associated with QTL A is located in ~2 kb intron shared
Figure 4 (A) MTX toxicity genome scan. The major chromosome arms are delineated by different background shading (white/yellow). The black
line is the scan of the observed data. To give an example of the results obtainable by chance alone, the grey line is a scan of a single permutation
of the observed data. Horizontal blue dotted lines indicate thresholds for various false positive rates (number of expected peaks per genome scan)
obtained via permutations. Vertical dashed red lines indicate the location of fly orthologs of previously identified candidate genes for
methotrexate toxicity. (B-C) Standardized founder haplotype means and SE at (B) QTL A and (C) QTL C. The number of each confidently assigned
(probability . 0.95) founder genotype is listed above each plot. Only means with at least five observations are plotted.
1308 | G. Kislukhin et al.
by all four alternatively transcripts of CG32626, so it may very well
have a phenotypic effect. Similarly the TE under QTL D1 is located in
the 650 bp 9UTR of CG32155, so is also likely to have a phenotypic
effect. Interestingly, though the TE association with QTL A is plausi-
bly implicated as being causative, it neither explains to total variation
explained by the QTL, nor the variation among founder means at the
QTL (e.g., Figure 4B). This finding suggests that this QTL is multi-
allelic, with some of the variation explained by a rare TE of large effect
and the remaining variation explained by regulatory SNP(s).
DISCUSSION
Using the DSPR panel, we were able to identify three QTL, two of
which lie directly over the D. melanogaster orthologs of known human
MTX candidate genes (QTL A and B; Figure 4A). This study validates
the use of Drosophila as a model system for chemotoxicity and is per-
haps the first example of standing phenotypic variation in flies and
humans being due to standing variation in the same genes Further-
more, we identify a fly gene (with a human ortholog) that represents
a new candidate gene worthy of additional study: PHGPx (human
ortholog GPx) (QTL C; Figure 4A). All together, our three identified
QTL explain 45% of the genetic variance in MTX toxicity. However,
given the known upward bias in effect sizes for detected QTL (i.e. the
Beavis effect), which is roughly proportional to the number of quasi-
independent statistical tests divided by the number of inbred lines
under study (Xu 2003), this estimate should be taken as an upper
limit. Overall, we have verified that Drosophila can serve as a model to
identify novel candidate genes important in chemotoxicity.
Chemotoxicity in flies may be due to regulatory
changes in fly orthologs of human candidate genes
Thus far, all of the candidate polymorphisms in humans that have
been studied represent amino acid variants (see Table S2). However,
the nonsynonymous SNPs in fly orthologs of human candidate genes
under peaks fail to explain the observed mapped segregating variation
in MTX toxicity. This finding suggests regulatory variants, controlling
the expression of these genes, are more likely the mapped QTL. Al-
though we are unable to definitively identify the causative variants for
our identified QTL, this result does suggest current human pharma-
cogenomics efforts that focus on amino acid encoding variants are
only scratching the surface of the genetic basis of chemotoxicity. One
of the advantages to using a stable panel of RILs designed to be
a community resource is the ability to assay multiple traits on the
same panel and integrate data across these studies. In this case, gene
expression data, especially utilizing ovary tissue, would be invaluable
in distinguishing between coding and regulatory changes as the caus-
ative variation. As these types of data become available, future studies
can integrate expression QTL data to help answer this question.
Is the genetic basis of chemotoxicity due to an allelic
series at each candidate gene?
When we test the complete set of biallelic SNPs in putative candidate
gene regions under a QTL peak, it is difficult to identify a single SNP
that explains the complete linkage signal. In the case of QTL D
perhaps this is not surprising, the broad peak in combination with
several excellent candidate genes clustering in this region suggests the
mapped QTL could be due to the underlying effects of polymorphisms
at several genes. That said, in the case of the other three mapped
genes, a single gene explaining the peak seems far more parsimonious.
The observation that no single SNP explains a given linkage signal,
and the additional observation that it appears that our estimated
haplotype effects do not nicely fall into two bins, suggests that more
than two variants are segregating in the DSRP at each candidate gene.
This is consistent with our first proof-of-principal publication from the
DSRP (King et al. 2012a) where the statistical analysis suggested more
than two alleles segregating at ADH explain ADH activity levels. It
remains to be seen how often mapped QTL support this heterogeneity
or allelic series model for the genetic architecture of complex traits.
Unreliability in the MTX dosing over blocks of the experiment
limited our sample size (see methods) and therefore our power to
detect QTL. The unreliability in dosing required us to discard several
experimental blocks in which the flies were obviously being consis-
tently over- or under-dosed, and likely resulted in greater heteroge-
neity in dosing within blocks than that seen in our earlier work
(Kislukhin et al. 2012). This heterogeneity resulted in lower broad-
sense heritabilities in this study than narrow-sense heritabilities ob-
served in Kislukhin et al. (2012). Genome-wide studies that include
large numbers of statistical tests are subject to stringent corrections for
multiple tests to minimize type I error. At the same time, the high
threshold for statistical significance results in high type II error. Here,
we have attempted to present a more nuanced interpretation of our
results considering both type I and type II error rates. For example, we
do not subject peaks that fall directly over candidate genes to the same
high threshold given the a priori expectation of a QTL at those loca-
tions. Our experimental design, crossing pA and pB RILs and mea-
suring F1 individuals, requires us to fit a model with more degrees of
freedom then other designs that could be considered, which also
negatively impacts our power (King et al. 2012b). However, we believe
some sort of outcrossing design is critical when measuring a life his-
tory trait such as post-treatment fecundity. Any direct measurements
on the RILs carry the risk of mapping variation for inbreeding de-
pression and this risk is especially high for life history traits.
Although we identified only three QTL using our model and
criteria for significance, we likely missed many more genes known to
be involved in the methotrexate pathway and methotrexate toxicity.
Simulation studies show that we need to assay upward of 800 line
crosses to reliably detect QTL contributing 5% to segregating variation
(c.f. King et al. 2011b). To improve the power of our study in the
future, the number of crosses used should be maximized and we
should future optimize drug delivery. We feel with improvement in
our first generation assays of toxicity, such gains can be realistically
achieved. Our assay may also miss some genes completely if our
original 15 founders are not segregating functional variants of measur-
able effect. Along this line a recent publication (Zichner et al. 2013)
showed that the DGRP (Mackay et al. 2012) is segregating a presence/
absence polymorphism of GstE5, whereas we see no evidence for this
event in the DSPR. If this presence/absence polymorphism impacted
MTX toxicity it could not be mapped in the DSPR.
It is clear from this study that Drosophila is a powerful model
system for identifying genetic variants underlying traits of human
interest. In addition to showing a similar genetic basis for MTX tox-
icity between humans and Drosophila, we were able to identify one
novel MTX toxicity human target gene, GPx. Given it is currently
unclear how this gene fits into the pharmacodynamic and/or the
pharmacokinetic pathway of the drug (Figure 2), an exciting avenue
for future research is confirming the role of this gene in human MTX
toxicity and characterizing its role in the pathway.
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